NanoTherm™
NanoActivator®
Stage 1 Completed
Enrollment and Treatment of Stage 1 Completed
MagForce USA has completed enrollment and treatment for Stage 1 and prepares for the next stage of its pivotal, single-arm study for the focal ablation of intermediate risk prostate cancer with NanoTherm therapy.